ReviewCancer research2019
Are Platelets the Primary Target of Aspirin's Remarkable Anticancer Activity?
Review in Cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- New Primary and Secondary Prevention Measures for Cutaneous Melanoma: A Systematic Review.Cancer reports (Hoboken, N.J.) · 2026Pooled it
- Aspirin use and ovarian cancer risk using extended follow-up of the PLCO Cancer Screening Trial.Gynecologic oncology · 2020Trial
- Thrombopoiesis meets tumorigenesis: unlocking the diagnostic and prognostic potential of platelet indices in breast cancer- a narrative review.Annals of medicine and surgery (2012) · 2026Review
- FOXM1 regulates platelet-induced anoikis resistance in pancreatic cancer cells.Cell communication and signaling : CCS · 2026Article
- Tumor-educated-platelets interact with breast cancer-stem-cells via P-selectin-PSGL1 and ensure stemness and metastasis through WNT-β-catenin-VEGF-VEGFR2 intra-cellular signaling: therapeutic modulation by aspirin.Breast cancer research : BCR · 2025Article
- Effect of the Combination of Concomitant Drugs on Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.Cancer reports (Hoboken, N.J.) · 2025Article
- The Expendables: Overlooked Medications with Anti-Cancer Properties.Current oncology reports · 2025Review
- Aspirin's effect on macrophages beyond its chemopreventive role in inflammation and cancer.Inflammopharmacology · 2025Review
- Low-dose aspirin and non-aspirin non-steroidal anti-inflammatory drugs and epithelial ovarian cancer survival: a registry-based cohort study in Norway.BMC cancer · 2025Article
- Differential Causal Effects of Common Analgesics on Breast Cancer Risk and Survival: Evidence from Mendelian Randomization.International journal of women's health · 2025Article
- Post-Diagnostic Aspirin Use in Breast Cancer Treatment: A Systematic Review and Meta-Analysis of Survival Outcomes with Trial Sequential Analysis Validation.Diagnostics (Basel, Switzerland) · 2024Article
- Acetylsalicylic Acid with Ascorbate: A Promising Combination Therapy for Solid Tumors.Drugs in R&D · 2024Article
- Using aspirin to prevent and treat cancer.Inflammopharmacology · 2024Review
- Aspirin and cancer treatment: systematic reviews and meta-analyses of evidence: for and against.British journal of cancer · 2024Article
- Synthesis, crystal structure andActa crystallographica. Section E, Crystallographic communications · 2023Article
- Survival Analysis of 1140 Patients with Biliary Cancer and Benefit from Concurrent Renin-Angiotensin Antagonists, Statins, or Aspirin with Systemic Therapy.The oncologist · 2023Article
- Aspirin inhibits the biological behavior of gallbladder carcinoma cells by modulating vascular endothelial growth factor.American journal of translational research · 2023Article
- Platelets in the tumor microenvironment and their biological effects on cancer hallmarks.Frontiers in oncology · 2023Review
- The association between aspirin use and immune-related adverse events in specific cancer patients receiving ICIs therapy: analysis of the FAERS database.Frontiers in pharmacology · 2023Article
- Scoping Review on Platelets and Tumor Angiogenesis: Do We Need More Evidence or Better Analysis?International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Aspirin, when administered at low doses, has emerged as a powerful anticancer drug due to both chemopreventive activity against many forms of cancer and its ability to block metastases when administered postdiagnosis. Platelets, which are often elevated in circulation during the latter stages of cancer, are known to promote epithelial-mesenchymal transition, cancer cell growth, survival in circulation, and angiogenesis at sites of metastases. Low-dose aspirin has been demonstrated to block this procarcinogenic action of platelets. In this article, we present evidence that aspirin's unique ability to irreversibly inhibit platelet cyclooxygenase-1 is a key mechanism by which aspirin exerts anticancer activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.